Ionis Pharmaceuticals, Inc.
MODULATION OF HSD17B13 EXPRESSION

Last updated:

Abstract:

Provided herein are methods, compounds, and compositions for reducing expression of HSD17B13 in a cell or individual. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a liver disease, metabolic disease, or cardiovascular disease or disorder, including but not limited to NASH, in an individual.

Status:
Application
Type:

Utility

Filling date:

21 Mar 2019

Issue date:

7 Jan 2021